AngioDynamics (ANGO) has just closed out FY 2026 with fourth quarter revenue of US$86.6 million and a basic EPS loss of US$0.27, alongside a trailing twelve month revenue line of US$320.2 million and a basic EPS loss of US$0.88. Over recent quarters the company has seen quarterly revenue move from US$72.0 million in FY 2025 Q3 to US$80.2 million in FY 2025 Q4, then to a range between US$75.7 million and US$86.6 million across FY 2026, while basic EPS losses have shifted from US$0.11 in FY 2025 Q3 to US$0.27 in FY 2026 Q4. For investors, the latest print keeps the focus firmly on how AngioDynamics manages profitability and margins from here, as the revenue base contrasts with continued net losses.
See our full analysis for AngioDynamics.With the headline numbers on the table, the next step is to compare these results with the most common AngioDynamics narratives to see which storylines the data supports and which ones start to look stretched.
See what the community is saying about AngioDynamics
Losses on US$320 million revenue keep profitability in focus
- Over the last twelve months, AngioDynamics generated US$320.2 million in revenue but reported a net loss of US$36.7 million and a basic EPS loss of US$0.88, with quarterly losses ranging from US$6.4 million to US$11.4 million in FY 2026.
- What stands out for the bullish narrative is that forecasts in the data point to earnings growing 72.2% per year and turning positive within about three years. This sits against a five year history where losses increased about 14.3% annually, so investors have to weigh the projected turnaround against the current trailing loss profile.
Unprofitable today, with bears focused on loss trend
- Across FY 2026, AngioDynamics reported quarterly net losses between US$6.4 million and US$11.4 million, and over the last year the company recorded a total loss of US$36.7 million, while analysis data notes that losses have grown about 14.3% per year over the past five years.
- Bears highlight that even though forecasts point to future profitability, the business is still reporting adjusted and GAAP net losses, and that this pattern of loss making can pressure funding and margin ambitions if costs like tariffs, R&D and reimbursement delays continue to weigh on earnings without a clear shift in the reported net income trend.
- This bear concern is echoed by FY 2026 EPS figures, where each quarter shows a per share loss between US$0.15 and US$0.27 rather than any quarter breaking into positive territory.
- Combined with a twelve month basic EPS loss of US$0.88, the current earnings record leaves little room in the reported numbers to counter the cautious view that profitability targets rely heavily on future execution rather than recent financial history.
Valuation gap versus DCF fair value and P/S peers
- AngioDynamics trades at a P/S of 1.9x, which sits below the 2.7x multiple cited for the US Medical Equipment industry and the 6.7x peer average, and below a DCF fair value of US$22.35 per share and an analyst price target reference of US$20.00 compared with the current US$14.47 share price.
- Supporters of the bullish view point to this valuation gap as a potential reward. They argue that if the projected 72.2% annual earnings growth and path to profitability play out, then the combination of discounted P/S and the gap to both the US$22.35 DCF fair value and the US$20.00 analyst target could offer upside, while critics can counter that the low multiple and discount also reflect the ongoing twelve month loss of US$36.7 million and the current absence of positive EPS.
- For the bullish case, the fact that the DCF fair value sits about US$7.88 above the current share price suggests the market is not yet pricing in the modeled earnings path, at least according to the supplied analysis.
- For the cautious side, the same figures can be read as a reminder that valuation signals are contingent on AngioDynamics shifting from a trailing EPS loss of US$0.88 to the positive earnings that forecasts and narratives discuss.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AngioDynamics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If the mixed signals around AngioDynamics have you weighing both risk and opportunity, consider reviewing the numbers yourself and stress testing your own expectations against the data that supports 3 key rewards.
See What Else Is Out There Beyond AngioDynamics
AngioDynamics is still reporting quarterly and twelve month losses, with EPS in the red and profitability targets relying heavily on future execution rather than recent results.
If those continuing losses and execution risks make you want more resilient options, check out 78 resilient stocks with low risk scores to quickly focus on companies with steadier profiles and lower perceived risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com